Zhejiang Medicine Co Ltd
SSE:600216

Watchlist Manager
Zhejiang Medicine Co Ltd Logo
Zhejiang Medicine Co Ltd
SSE:600216
Watchlist
Price: 14.06 CNY 0.72% Market Closed
Market Cap: 13.5B CNY

Zhejiang Medicine Co Ltd
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zhejiang Medicine Co Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang Medicine Co Ltd
SSE:600216
Tax Provision
-ÂĄ199.4m
CAGR 3-Years
5%
CAGR 5-Years
-7%
CAGR 10-Years
-15%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Tax Provision
-ÂĄ873.9m
CAGR 3-Years
-17%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Tax Provision
-ÂĄ424.7m
CAGR 3-Years
0%
CAGR 5-Years
-7%
CAGR 10-Years
-16%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Tax Provision
-ÂĄ1B
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
-13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Tax Provision
-ÂĄ1.1B
CAGR 3-Years
-25%
CAGR 5-Years
-6%
CAGR 10-Years
-9%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Tax Provision
-ÂĄ270.6m
CAGR 3-Years
N/A
CAGR 5-Years
-126%
CAGR 10-Years
N/A
No Stocks Found

Zhejiang Medicine Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

Zhejiang Medicine Co., Ltd., a stalwart in the pharmaceutical industry, traces its roots back to a time when China's economic landscape was rapidly transforming. Founded amidst the burgeoning wave of Chinese industrial expansion, the company made a calculated entry into the biopharmaceutical sector, a move that positioned it as an indispensable player in the realm of vitamins and antibiotics. Headquartered in the populous province of Zhejiang, the firm quickly honed its expertise in the manufacturing and export of fat-soluble vitamins, notably vitamin E, which became one of its hallmark products. Their robust production facilities and rigorous adherence to quality standards have not only fueled domestic demand but also secured a strong foothold in international markets, particularly Europe and the Americas. Zhejiang Medicine has crafted a diversified portfolio that spans active pharmaceutical ingredients (APIs) and advanced intermediates, offering a spectrum of products utilized by various health and pharmaceutical companies worldwide. A key revenue driver for the company lies in its vertical integration strategy, which enables it to maintain meticulous oversight over the entire production process, from raw materials to finished goods. The company’s commitment to R&D is evident in its investments in technology and innovation, allowing it to improve production efficiency and develop new compounds that cater to the evolving demands of the health sector. This approach not only insulates the company from market volatility but also fortifies its competitive position in a dynamic industry.

Intrinsic Value
25.13 CNY
Undervaluation 44%
Intrinsic Value
Price

See Also

What is Zhejiang Medicine Co Ltd's Tax Provision?
Tax Provision
-199.4m CNY

Based on the financial report for Sep 30, 2025, Zhejiang Medicine Co Ltd's Tax Provision amounts to -199.4m CNY.

What is Zhejiang Medicine Co Ltd's Tax Provision growth rate?
Tax Provision CAGR 10Y
-15%

Over the last year, the Tax Provision growth was -16%. The average annual Tax Provision growth rates for Zhejiang Medicine Co Ltd have been 5% over the past three years , -7% over the past five years , and -15% over the past ten years .

Back to Top